Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
'I am delighted to welcome Dr. Perrin Wilson to the Climb Bio management team,' said Aoife Brennan, President and CEO of Climb Bio. 'Perrin brings extensive experience and a track record of success across large pharma and biotech to Climb Bio. As Chief Business Officer, she will lead the Company's pre-commercial planning, communications, and business development efforts. Perrin's proven expertise in negotiating pivotal transactions, combined with her deep commercial acumen, will be invaluable to Climb Bio as we advance our ambition of becoming a leader in developing best-in-class treatments for patients with immune-mediated diseases, where the need for innovative solutions remains profound.'
'This is an exciting time to join Climb Bio, which has both a growing pipeline of differentiated programs and a strong financial position,' said Dr. Wilson. 'I look forward to working with the team as we progress our key assets, budoprutug and CLYM116, continue building the company, and achieve our mission of bringing better treatment options to people living with immune-mediated diseases.'
Before joining Climb Bio, Dr. Wilson served as Senior Vice President, Business Development and Strategy at Nuvalent and held positions of increasing responsibility at Forma Therapeutics/Novo Nordisk, including Head of Forma Business Development and Integration Management Office, Vice President Business Development and Senior Director Global Marketing, Sickle Cell Disease Strategy. While at Forma, she led the $1.1 billion acquisition by Novo Nordisk and out-licensing of Forma's oncology portfolio and was responsible for developing the global brand plan and supporting the ex-US and lifecycle management strategy for the sickle cell program. Before that, Dr. Wilson spent seven years at Takeda in various business development and commercial roles leading multiple transactions to strengthen Takeda's oncology pipeline, including the $5.2 billion acquisition of ARIAD, and leading the global strategy and pre-launch preparations for Takeda's myelodysplastic syndromes program. Earlier in her career, she spent seven years at Forest Laboratories, Inc. in both business development and commercial roles. Dr. Wilson received her B.Sc. from Lafayette College and Ph.D. from The Rockefeller University.
About Climb Bio, Inc.Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's pipeline includes budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.
Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug and CLYM116; the anticipated benefits of Climb Bio's license agreement with Mabworks; the sufficiency of Climb Bio's cash resources for the period anticipated; and other statements containing the words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'would,' 'will,' 'working' and similar expressions. Forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc. and its license agreement with Mabworks; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; Climb Bio's ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio's actual results to differ materially from those contained in the forward-looking statements, see the 'Risk Factors' section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio's most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio's views as of the date hereof and should not be relied upon as representing Climb Bio's views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio's views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law.
InvestorsChris Brinzey ICR Healthcarechris.brinzey@icrhealthcare.com339-970-2843
MediaJon YuICR Healthcarejon.yu@icrhealthcare.com475-395-5375Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
UBS Reiterates Buy on AppLovin (APP) With $540 PT After Q2 Beat
AppLovin Corporation (NASDAQ:APP) is one of the . On August 7, UBS analyst John Hodulik reiterated a Buy rating on the stock with a $540.00 price target. The rating affirmation follows Applovin's second quarter results, beating Wall Street's targets and guiding higher for sales in the current period. The firm increased its fiscal year 2026 EBITDA estimate to $6.18 billion, above the Street consensus of $5.65 billion. This was driven by better-than-expected gaming-related trends in the second and third quarters. The firm is optimistic that AppLovin's staggered rollout of its self-serve web-based ad platform, which begins in October, reduces medium-term risk for web-based advertising revenue growth. The rollout will start with referral-based advertisers before moving to general availability in the first half of 2026. An experienced financial analyst working with a laptop, illustrating the level of financial expertise. This will allow the company to deliver multi-quarter revenue growth particularly with expansion into international markets. Once the ad platform becomes generally available, advertisers will likely spend faster. The stock dip after-hours is therefore a buying opportunity: 'From here we see scope for GA advertisers to ramp spend faster as they benefit from more iteration on the platform. All-in, we'd take advantage of the AH weakness and reiterate our Buy rating on the basis of attractive risk/reward (2.1x), attractive valuation (37x FY26 P/E vs 42% 3-YR EPS CAGR) and improving catalyst path visibility.' AppLovin Corporation (NASDAQ:APP) provides a leading marketing platform powered by AI technology. While we acknowledge the potential of APP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Why Rigetti Computing Stock Soared 9.3% This Week
Key Points A potential breakthrough from researchers at USC sent Rigetti stock higher. A new particle could help quantum companies solve quantum's error issue. The technology could still be many years away. 10 stocks we like better than Rigetti Computing › Shares of Rigetti Computing (NASDAQ: RGTI) jumped this week. The quantum computing start-up's stock rose 9.3% from last Friday's close. The move came as the S&P 500 and the Nasdaq-100 rose 2.4% and 3.7%, respectively. Rigetti and other quantum stocks were lifted this week by news that researchers at the University of Southern California may have found a way around obstacles the technology faces in its development. A "rescued" particle could boost quantum Researchers at the University of Southern California said that they had identified a new type of particle they call "neglectons," which could help solve one of quantum computing's biggest issues. The particles earned their name from their once-overlooked status; researchers had previously dismissed them as "mathematical garbage." Quantum computing faces a number of hurdles in its ongoing development. Chief among them is the inherent difficulty in error correction. These systems are fragile and hard to keep from degrading. The new particles could help scientists solve this issue through an approach called "braiding." Investors should remain cautious While the news is positive, it by no means indicates the issue is solved -- or is close to being solved. This is a highly experimental field at the very edge of human knowledge and theory, let alone practical engineering. I think many investors are getting ahead of themselves, and it could be many years, if not decades, before we see viable quantum computing at scale. Rigetti is one of the more promising quantum companies, but at its current valuation, I would not invest. Do the experts think Rigetti Computing is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Rigetti Computing make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Rigetti Computing Stock Soared 9.3% This Week was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
Why Clean Energy Fuels Stock Raced Nearly 13% Higher Today
Key Points The energy company delivered better-than-expected numbers in its latest earnings release. It beat on both the top and bottom lines with second-quarter results. 10 stocks we like better than Clean Energy Fuels › Clean Energy Fuels (NASDAQ: CLNE), a company that sells renewable natural gas (RNG) as a fuel for automobiles, scored a clean win on the stock exchange Friday. Its shares zoomed almost 13% higher after it unveiled its latest set of quarterly results, which, among other things, featured a double beat on analyst estimates. With that performance, it crushed the 0.8% increase of the S&P 500 index. Confidence renewed after results published Clean Energy Fuels' second quarter saw the company post revenue of $102.6 million, which was nearly 5% higher on a year-over-year basis. Non-GAAP (adjusted) net income fell to $337,000, shaking out to less than $0.01 per share. Image source: Getty Images. Despite the bottom-line decline, analysts were expecting notably worse results. On average, they were modeling slightly over $94 million for revenue and a net loss of $0.06 per share. In its earnings release, Clean Energy Fuels CEO Andrew Littlefair said, "RNG remains the most immediate and cost-effective clean transportation fuel, as we see continued strong demand reflected in our solid second quarter results." Littlefair also pointed out that the government's recently passed "big, beautiful bill" supports the RNG market. Its extension of the clean fuel production tax credit should be a boon for RNG producers and suppliers. Powering big fleets Clean Energy Fuels is doing quite well in its rather limited niche, and during the quarter, it executed new supply arrangements with a number of municipal transit fleets, including LA Metro in Los Angeles. Such customers tend to be long-term and reliable, so it'll be worthwhile for investors to keep an eye on how the segment continues to develop for the company. Should you invest $1,000 in Clean Energy Fuels right now? Before you buy stock in Clean Energy Fuels, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Clean Energy Fuels wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Clean Energy Fuels Stock Raced Nearly 13% Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
